JOSHUA MORALES, MD

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

Administration of chemotherapy into vein, 1 hour or less

New patient office or other outpatient visit, 60-74 minutes

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

New patient office or other outpatient visit, 45-59 minutes

Injection, zoledronic acid, 1 mg

Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes

Administration of additional new drug or substance into vein, 1 hour or less

Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg

Established patient office or other outpatient visit, 40-54 minutes

Administration of additional new drug or substance into vein using push technique

Drawing of blood for a medical problem

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Injection, carboplatin, 50 mg

Established patient office or other outpatient visit, 30-39 minutes

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Infusion into a vein for hydration, 31-60 minutes

Vitamin d-3 level

Injection of drug or substance into vein

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Administration of chemotherapy into vein, each additional hour

Established patient office or other outpatient visit, 20-29 minutes

Nephelometry, test method using light

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Injection, pembrolizumab, 1 mg

Injection, bortezomib, 0.1 mg

Injection, palonosetron hcl, 25 mcg

Irrigation of implanted venous access drug delivery device

Injection of additional new drug or substance into vein

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Carcinoembryonic antigen (cea) protein level

Injection of drug or substance under skin or into muscle

Psa (prostate specific antigen) measurement, total

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Blood test, thyroid stimulating hormone (tsh)

Cyanocobalamin (vitamin b-12) level

Infusion into a vein for hydration, each additional hour

Folic acid level, serum

Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services

Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or

Thyroxine (thyroid chemical), free

Blood test, comprehensive group of blood chemicals

Measurement of immunoglobulin light chains

Ferritin (blood protein) level

Gammaglobulin (immune system protein) measurement

Blood test, basic group of blood chemicals (calcium, total)

Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count